Wednesday, April 7, 2010 as of 11:14 AM ET
Alcon incorporated and with corporate headquarters, in Hünenberg, Switzerland, is a global medical company specializing in eye care products.
Read More at Wikipedia ›
Nestle snatched Pfizer's (NYSE:PFE) infant nutrition business on Monday for nearly $12 billion, making the Swiss food group the largest player in the key Asia-Pacific market.
The $11.85 billion sticker price trumped reports in the press from last week that indicated a $10 billion buyout of the business unit, which generates 85% of its sales from emerging markets.By agreeing to the all-cash deal, Nestle has got its hands on a division that will complement its infant nutrition business and that is expected to post 2012 sales of $2.4 billion. Sales jumped 15% in 2011 to $2.1 billion."This acquisition underlines our commitment to be the world's leading nutrition, health and wellness company," Nestle CEO Paul Bulcke said in a statement. "The combined entities will enable us to deepen our engagement with consumers, offering them a wider choice of nutritious food to ensure their children make a healthy start to a healthy life."Nestle, which is already the world's largest food company, said it ...Novartis's <NOVN.VX> recently acquired eyecare business Alcon is facing a U.S. government investigation into alleged healthcare fraud, the Swiss drugmaker said on Tu...
Swiss food giant Nestle S.A. (NESN.VX) Wednesday reported a 13% drop in first-half profit after being hit by rising raw material prices and the soaring Swiss franc.T...
By Saeed Azhar and Lee Chyen YeeSINGAPORE/HONG KONG (Reuters) - Nestle <NESN.VX>, the world's largest food company, offered to buy 60 percent of Chinese candies and ...
By Lee Chyen Yee and Silke KoltrowitzHONG KONG/ZURICH (Reuters) - Nestle <NESN.VX>, the world's largest food company, is among companies in talks with Chinese candie...
Shares of Novartis (NYSE:NVS) rose more than 3% in morning trade after the company revealed a stronger-than-expected jump in first-quarter revenue, led by recently i...
By Katie ReidZURICH (Reuters) - Novartis AG <NOVN.VX> is likely to be the latest drugmaker to show it too has been hit by a collapse in sales of pandemic flu medicin...
ZURICH -(Dow Jones)- Swiss firms are far more upbeat on dealmaking this year, though experts don't expect a return to levels of mergers and acquisitions seen before ...
BASEL -(Dow Jones)- Novartis AG (NVS) Thursday warned of a tough 2011 as imminent patent expiries and drug price reductions linked to the U.S. health care reform wil...
BASEL -(Dow Jones)- Switzerland's Novartis AG (NVS) missed forecasts Thursday as it reported a 2% drop in fourth-quarter net profit and warned that price cuts, gener...
FOX Business: The Power to ProsperHeld back by the tumbling euro, stocks landed in the red on Wednesday, backing the Dow away from levels unseen since September 2008...
FBN's Connell McShane on Novartis' purchase of the remaining share of Alcon for $12.9 billion.
FBN's Connell McShane on Novartis agreeing to buy the remaining 23% stake of Alcon .
LONDON -- Novartis AG's (NVS) multiple sclerosis pill Gilenya has been recommended for use on the U.K.'s publicly funded National Health Service, a welcome decision ...
Novartis (NVS) said Friday it acquired the rights to an experimental eye treatment from ThromboGenics (THR.BT) of Belgium to sell it outside the U.S., in a deal that...
VEVEY, Switzerland -( Dow Jones )- Nestle SA (NESN.VX) Thursday maintained its growth targets despite expectations of a tough year ahead as it reported a drop in net...
VEVEY, Switzerland -( Dow Jones )- Nestle SA (NESN.VX) Thursday maintained its growth targets despite expectations of a tough year ahead as it reported a drop in net...
Switzerland's Novartis AG (NVS) Wednesday said its profitability will decline this year due to competition from generic rivals, continued drug price cuts and the nee...
Switzerland's Novartis AG (NVS) Wednesday issued a cautious earnings outlook for 2012 as it reported a 46% drop in fourth-quarter net profit, hit by restructuring co...
TAKING THE PULSE: European pharmaceutical companies are expected to give mixed performances when announcing fourth-quarter results this month and next, with some mor...
Quotes delayed at least 15 minutes. Real-time quotes provided by BATS Exchange. Market Data provided by Interactive Data (Terms & Conditions). Powered and Implemented by Interactive Data Managed Solutions. Company fundamental data provided by Morningstar. Earnings estimates data provided by Zacks. Mutual fund data provided by Lipper. Economic data provided by Econoday. Dow Jones & Company Terms & Conditions.
This material may not be published, broadcast, rewritten, or redistributed. ©2012 FOX News Network, LLC. All rights reserved.
